Amniotic Membrane Shows Potential in Patients with Graft Versus Host Disease-induced Dry Eye Disease
Amniotic membrane appears to improves dry eye disease (DED) signs and symptoms in patients with oGVHD-induced dry eye disease, according to data presented at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting.
A retrospective, chart review included 14 patients (26 eyes) with ocular surface damage and DED associated with chronic graft-versus-host disease who were treated with cryopreserved amniotic membrane (Prokera Slim). All patients saw subjective improvement of symptoms, including foreign body sensation, photophobia, and ability to perform daily tasks after an average 2.2 ± 0.9 treatments over 17.8 ± 10.9 months (range: 1.6- 35.0),
Decreased corneal staining (n = 26), improvement of filamentary keratopathy (n = 9), and decreased National Institutes of Health (NIH)-oGVHD score (n = 11), were also noted.
Contreras MP, et al. Management of Gvhd-induced dry-eye disease with amniotic membrane. American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.